Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...

Researchers at Peking University have discovered that a filamentous gut fungus, Fusarium foetens, can reverse metabolic ...

AMSTERDAM — A once daily, 50 mg dose of efruxifermin reduced fibrosis at 96 weeks in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) compared with ...

Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring of the organ, ...

Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 ...

The diabetes and weight loss drug semaglutide reversed liver scarring and inflammation. It’s among several drugs in the works for the condition MASH.

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new ...

Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment landscape for patients with metabolic dysfunction-associated steatohepatitis ...